Anavex Life Sciences Corp (AVXL)

[Steady_T]

The PR described this as the biomarker...

Data showed that ANAVEX2-73 treatment resulted in a significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints - Rett Syndrome Behaviour Questionnaire (RSBQ) and CGI-I (assessment scale for determining the effects of mental health treatment)

So the data showed the biomarker improvement AND showed how the biomarker correlated with clinical improvements. That is something that Adu** did not do.

Seems to me that 2-73 has a much stronger case for approval.